A groundbreaking injectable HIV prevention drug will be available for just $40 a year in over 100 countries by 2027, thanks to agreements between Unitaid, the Gates Foundation, and Indian pharmaceutical companies.
The EU has recommended lenacapavir, an injectable drug for HIV prevention, which could drastically reduce transmission rates. With nearly 100% effectiveness, it promises a new era in combating HIV.
The European Medicines Agency has recommended the approval of lenacapavir, a twice-yearly injectable drug that could revolutionize HIV prevention and significantly reduce transmission rates globally.
